Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Fig. 2

Cumulative risk curve of new-onset AF for the study cohorts treated with metformin plus DPP-4 inhibitor versus other hypoglycemic agents after propensity score weighting. DPP4i group (solid line) shows a significantly lower cumulative risk of new-onset AF compared with non-DPP4i group in patients treated with metformin (dotted line). DPP4i dipeptidyl peptidase-4 inhibitor

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840